Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 10/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20639946 | 0.85 | IGF1R (0.52) | IGF1RAKR1C3MAPTMAPK1KMT2A | |
| SCHEMBL30270125 | 0.85 | IGF1R (0.52) | IGF1RAKR1C3MAPTMAPK1KMT2A | |
| SCHEMBL20639675 | 0.85 | OGA (0.54) | IGF1RAKR1C3MAPTOGAROCK2 | |
| SCHEMBL30270105 | 0.84 | IGF1R (0.49) | IGF1RAKR1C3MAPTMAPK1DRD2 | |
| SCHEMBL20639882 | 0.84 | IGF1R (0.49) | IGF1RAKR1C3MAPTMAPK1DRD2 | |
| SCHEMBL609900 | 0.84 | ESR1 (0.39) | IGF1R | |
| SCHEMBL1589426 | 0.84 | ESR1 (0.39) | IGF1R | |
| SCHEMBL11685 | 0.84 | ESR1 (0.39) | IGF1R | |
| SCHEMBL25160649 | 0.83 | IGF1R (0.40) | IGF1RAKR1C3MAPTOGAMAPK1 | |
| SCHEMBL20639952 | 0.83 | IGF1R (0.50) | IGF1RAKR1C3MAPTROCK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| CN-108779094-B | Metalloenzyme inhibitor compounds | NQP 1598公司 | 2021-11-16 | — | — | CN | disclosed |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | IGF1R 1433/4885AKR1C3 1506/4885MAPT 2507/4885 |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | IGF1R 1433/4885AKR1C3 1506/4885MAPT 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.